Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2009 1
2010 1
2012 2
2013 2
2014 5
2015 3
2016 3
2017 3
2018 3
2019 5
2020 7
2021 15
2022 18
2023 8
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients.
Lu N, Liu J, Xu M, Liang J, Wang Y, Wu Z, Xing Y, Diao F. Lu N, et al. Int J Gen Med. 2021 Nov 4;14:7647-7657. doi: 10.2147/IJGM.S335592. eCollection 2021. Int J Gen Med. 2021. PMID: 34764678 Free PMC article.
METHODS: Our present work analyzed genetic mutation data of OC patients obtained from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) cohorts, and we identified 11 frequently mutated genes, namely, APOB, CSMD3, DST, FAT3, FLG, …
METHODS: Our present work analyzed genetic mutation data of OC patients obtained from The Cancer Genome Atlas (TCGA) and Internationa …
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.
Möhrmann L, Werner M, Oleś M, Mock A, Uhrig S, Jahn A, Kreutzfeldt S, Fröhlich M, Hutter B, Paramasivam N, Richter D, Beck K, Winter U, Pfütze K, Heilig CE, Teleanu V, Lipka DB, Zapatka M, Hanf D, List C, Allgäuer M, Penzel R, Rüter G, Jelas I, Hamacher R, Falkenhorst J, Wagner S, Brandts CH, Boerries M, Illert AL, Metzeler KH, Westphalen CB, Desuki A, Kindler T, Folprecht G, Weichert W, Brors B, Stenzinger A, Schröck E, Hübschmann D, Horak P, Heining C, Fröhling S, Glimm H. Möhrmann L, et al. Nat Commun. 2022 Aug 2;13(1):4485. doi: 10.1038/s41467-022-31866-4. Nat Commun. 2022. PMID: 35918329 Free PMC article.
The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is unclear. Here, we use comprehensive molecular characterization by whole genome/exome, transcriptome and methylome analysis in 70 CUP patients to reveal substantial mutational heterogeneity …
The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is unclear. Here, we use comprehensive molecular cha …
Significance of KDM6A mutation in bladder cancer immune escape.
Chen X, Lin X, Pang G, Deng J, Xie Q, Zhang Z. Chen X, et al. BMC Cancer. 2021 May 29;21(1):635. doi: 10.1186/s12885-021-08372-9. BMC Cancer. 2021. PMID: 34051747 Free PMC article.
BACKGROUND: Bladder cancer (BC) is the fourth most prevalent neoplasm in men and is associated with high tumour recurrence rates, leading to major treatment challenges. ...Here, we explored the potential role of KDM6A in regulating the antitumor immune response. METHODS: W …
BACKGROUND: Bladder cancer (BC) is the fourth most prevalent neoplasm in men and is associated with high tumour recurrence rates, lea …
Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma.
Loh JW, Lee JY, Lim AH, Guan P, Lim BY, Kannan B, Lee ECY, Gu NX, Ko TK, Ng CC, Lim JCT, Yeong J, Lim JQ, Ong CK, Teh BT, Chan JY. Loh JW, et al. Commun Biol. 2023 Apr 27;6(1):461. doi: 10.1038/s42003-023-04856-5. Commun Biol. 2023. PMID: 37106027 Free PMC article.
In the AS-HN cohort, we observed recurrent somatic mutations in CSMD3 (18%), LRP1B (18%), MUC16 (18%), POT1 (16%) and TP53 (16%). ...
In the AS-HN cohort, we observed recurrent somatic mutations in CSMD3 (18%), LRP1B (18%), MUC16 (18%), POT1 (16%) and TP53 (16%). ...
Identification of CD8(+) T Cell Related Biomarkers in Ovarian Cancer.
Li L, Chen D, Luo X, Wang Z, Yu H, Gao W, Zhong W. Li L, et al. Front Genet. 2022 May 27;13:860161. doi: 10.3389/fgene.2022.860161. eCollection 2022. Front Genet. 2022. PMID: 35711935 Free PMC article.
Background: Immunotherapy is a promising strategy for ovarian cancer (OC), and this study aims to identify biomarkers related to CD8(+) T cell infiltration to further discover the potential therapeutic target. Methods: Three datasets with OC transcriptomic data were downlo …
Background: Immunotherapy is a promising strategy for ovarian cancer (OC), and this study aims to identify biomarkers related to CD8( …
Integrated characterisation of cancer genes identifies key molecular biomarkers in stomach adenocarcinoma.
Wang H, Shen L, Li Y, Lv J. Wang H, et al. J Clin Pathol. 2020 Sep;73(9):579-586. doi: 10.1136/jclinpath-2019-206400. Epub 2020 Feb 7. J Clin Pathol. 2020. PMID: 32034058 Free PMC article.
AIMS: Gastric cancer is one of the leading causes for cancer mortality. Recent studies have defined the landscape of genomic alterations of gastric cancer and their association with clinical outcomes. ...RESULTS: TTN, TP53, LRP1B, CSMD3, OBSCN, ARID1A, …
AIMS: Gastric cancer is one of the leading causes for cancer mortality. Recent studies have defined the landscape of genomic a …
Comprehensive Analyses of Ferroptosis-Related Alterations and Their Prognostic Significance in Glioblastoma.
Tian Y, Liu H, Zhang C, Liu W, Wu T, Yang X, Zhao J, Sun Y. Tian Y, et al. Front Mol Biosci. 2022 Jun 3;9:904098. doi: 10.3389/fmolb.2022.904098. eCollection 2022. Front Mol Biosci. 2022. PMID: 35720126 Free PMC article.
Then, the risk score predicting model containing 23 genes (CP, EMP1, AKR1C1, FMOD, MYBPH, IFI30, SRPX2, PDLIM1, MMP19, SPOCD1, FCGBP, NAMPT, SLC11A1, S100A10, TNC, CSMD3, ATP1A2, CUX2, GALNT9, TNFAIP6, C15orf48, WSCD2, and CBLN1) on the basis of "Ferroptosis.gene.cluster" …
Then, the risk score predicting model containing 23 genes (CP, EMP1, AKR1C1, FMOD, MYBPH, IFI30, SRPX2, PDLIM1, MMP19, SPOCD1, FCGBP, NAMPT, …
The immune subtypes and landscape of sarcomas.
Weng W, Yu L, Li Z, Tan C, Lv J, Lao IW, Hu W, Deng Z, Liu Z, Wang J, Xu M. Weng W, et al. BMC Immunol. 2022 Sep 24;23(1):46. doi: 10.1186/s12865-022-00522-3. BMC Immunol. 2022. PMID: 36153483 Free PMC article.
IMS1 showed an immune "hot" and immunosuppressive phenotype, the highest frequencies of CSMD3 mutation but the lowest frequencies of HMCN1 and LAMA2 mutations; these patients had the worst progression-free survival (PFS). ...
IMS1 showed an immune "hot" and immunosuppressive phenotype, the highest frequencies of CSMD3 mutation but the lowest frequencies of …
Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
Wu H, Yu Z, Liu Y, Guo L, Teng L, Guo L, Liang L, Wang J, Gao J, Li R, Yang L, Nie X, Su D, Liang Z. Wu H, et al. Cancer Commun (Lond). 2022 Dec;42(12):1367-1386. doi: 10.1002/cac2.12372. Epub 2022 Oct 20. Cancer Commun (Lond). 2022. PMID: 36264285 Free PMC article.
Furthermore, we found that tumor cells in GI-NECs first gain clonal mutations in TP53, RB1, NOTCH1 and APC, followed by subsequent whole-genome doubling (WGD) and post-WGD clonal mutations in LRP1B, CUB and Sushi multiple domains 3 (CSMD3), FAT tumor suppressor homolog 4 ( …
Furthermore, we found that tumor cells in GI-NECs first gain clonal mutations in TP53, RB1, NOTCH1 and APC, followed by subsequent whole-gen …
Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer.
Fan Z, Zhang Q, Feng L, Wang L, Zhou X, Han J, Li D, Liu J, Zhang X, Zuo J, Zou X, Cai Y, Sun Y, Wang Y. Fan Z, et al. Ann Transl Med. 2022 Feb;10(4):188. doi: 10.21037/atm-22-412. Ann Transl Med. 2022. PMID: 35280362 Free PMC article.
Meanwhile, the TP53 gene is one of the most frequently altered gene in non-small cell lung cancer (NSCLC) patients. Mutant TP53 (TP53-MUT) may lose tumor suppressor activity and gain tumor promoting functions, which play an important role in cancer risk, therapy res …
Meanwhile, the TP53 gene is one of the most frequently altered gene in non-small cell lung cancer (NSCLC) patients. Mutant TP53 (TP53 …
75 results